Literature DB >> 18316574

Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.

Yuanmei Lou1, Genc Basha, Robyn P Seipp, Bing Cai, Susan S Chen, Alexander R Moise, Andrew P Jeffries, Ray S Gopaul, Timothy Z Vitalis, Wilfred A Jefferies.   

Abstract

PURPOSE: Tpn is a member of the MHC class I loading complex and functions to bridge the TAP peptide transporter to MHC class I molecules. Metastatic human carcinomas often express low levels of the antigen-processing components Tapasin and TAP and display few functional surface MHC class I molecules. As a result, carcinomas are unrecognizable by effector CTLs. The aim of this study is to examine if Tapasin (Tpn) plays a critical role in the escape of tumors from immunologic recognition. EXPERIMENTAL
DESIGN: To test our hypothesis, a nonreplicating adenovirus vector encoding human Tpn (AdhTpn) was constructed to restore Tpn expression in vitro and in vivo in a murine lung carcinoma cell line (CMT.64) that is characterized by down-regulation of surface MHC class I due to deficiency in antigen-processing components.
RESULTS: Ex vivo, Tpn expression increased surface MHC class I and restored susceptibility of tumor cells to antigen-specific CTL killing, and AdhTpn infection of dendritic cells also significantly increased cross-presentation and cross-priming. Furthermore, tumor-bearing animals inoculated with AdhTpn demonstrated a significant increase in CD8(+) and CD4(+) T cells and CD11c(+) dendritic cells infiltrating the tumors. Provocatively, whereas syngeneic mice bearing tumors that were inoculated with AdhTpn a significant reduction in tumor growth and increased survival compared with vector controls, combining AdhTpn inoculation with AdhTAP1 resulted in a significant augmentation of protection from tumor-induced death than either component alone.
CONCLUSIONS: This is the first demonstration that Tpn alone can enhance survival and immunity against tumors but additionally suggests that Tpn and TAP should be used together as components of immunotherapeutic vaccine protocols to eradicate tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316574     DOI: 10.1158/1078-0432.CCR-07-1066

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

2.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

3.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

Review 4.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

5.  HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human glioma.

Authors:  Shan-Yi Zhang; Jun-Liang Li; Xin-Ke Xu; Mei-Guang Zheng; Cheng-Cai Wen; Fang-Cheng Li
Journal:  J Neurooncol       Date:  2011-04-26       Impact factor: 4.130

Review 6.  Antigen processing and immune regulation in the response to tumours.

Authors:  Emma Reeves; Edward James
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

7.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

8.  Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women.

Authors:  Ayshamgul Hasim; Mangnishahan Abudula; Reshalaiti Aimiduo; Jun-Qi Ma; Zhen Jiao; Gulzareye Akula; Ting Wang; Abulizi Abudula
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

9.  Loss of tapasin correlates with diminished CD8(+) T-cell immunity and prognosis in colorectal cancer.

Authors:  Lena Sokol; Viktor H Koelzer; Tilman T Rau; Eva Karamitopoulou; Inti Zlobec; Alessandro Lugli
Journal:  J Transl Med       Date:  2015-08-27       Impact factor: 5.531

10.  Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function.

Authors:  Andrés López-Albaitero; Robbie Mailliard; Trevor Hackman; Pedro A Andrade Filho; Xinhui Wang; William Gooding; Soldano Ferrone; Pawel Kalinski; Robert L Ferris
Journal:  J Immunother       Date:  2009-06       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.